Hengrui Pharma's subsidiary injectable SHR-A2102 has been approved for clinical use
Hengrui Pharma (01276.HK) announced that its subsidiary Suzhou Shengdiya Biopharmaceutical and Shanghai Hengrui Pharma have received the Drug Clinical Trial Approval Notice issued by the National Medical Products Administration regarding the injectable SHR-A2102, and will soon commence clinical trials.
The injectable SHR-A2102 is a targeted Nectin-4 antibody-drug conjugate (ADC) independently developed by the company and has intellectual property rights. Its effective payload is a topoisomerase I inhibitor (TOP1i). Various studies have shown that the high expression of Nectin-4 in tumors is closely related to tumor development and poor prognosis
Source: AASTOCKS The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments